Aldeyra Therapeutics, Inc. (ALDX) News
Track canonical SquawkNews coverage tagged to ALDX, Aldeyra Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 04:40 PM UTC
L
BTIG reiterates Buy rating on Aldeyra Therapeutics, $9 price target
BTIG reiterated their Buy rating on Aldeyra Therapeutics's stock with a price target of $9.00.The price target implies an upside of 675.9% from the Sep 28 close of $1.16.Key takeaways from the analyst notePositive Trial
EQUITY | Sep 29, 2026, 04:30 PM UTC
L
Aldeyra Intends to Submit FDA Formal Dispute Request for Reproxalap; Cash Runway Extended into 2029
Aldeyra intends to submit a Formal Dispute Resolution Request to the FDA appealing the March 16, 2026 Complete Response Letter for reproxalap and reports operational cash runway extended into 2029.Key Highlights:Original
REGULATION | Sep 29, 2026, 11:03 AM UTC
L
Aldeyra Therapeutics, Inc. (ALDX) To File FDA FDRR on Reproxalap; Cash Runway Into 2029
Aldeyra plans an FDA Formal Dispute Resolution Request for reproxalap after a March 16, 2026 CRL, with OND meeting expected in Q4 2026. The company also guided operational cash runway into 2029.Material DetailsContext by
REGULATION | Sep 29, 2026, 11:01 AM UTC
L
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U
REGULATION | Sep 29, 2026, 11:00 AM UTC
L
Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will hos
NEWS | Sep 28, 2026, 08:30 PM UTC
L
ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing
ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing
REGULATION | Jul 15, 2026, 09:09 PM UTC